Board summary
Key figures
51,614
Registered population
58.9% aged 18–64
14.7%
Aged 65+
ICB 20.0% · England 17.9%
45.2%
Ethnic minority (non-White)
41.9% Asian · England 9.6%
65.4%
In IMD quintile 1
ICB 30.6% · England 21.0%
~31,341
Core20 residents (est.)
Resident basis; registered basis ~34,738 · see page 3
7,027
Hypertension register
+2.56% in 3 yrs · England +5.60%
582
SMI register
51.5% of Pendle's
935
COPD register
Reviews +3.90% in 3 yrs
Forecast to 2030
7,493
Hypertension patients, 2030
+466 on today
100.0%
QRISK ≥20% on statins, 2030
+12.02pp over 3 yrs
3.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure and diabetes control lag.
Under-80 hypertension control is 63.5% (England 67.8%) after a -2.4% three-year change (England +3.2%), while non-frail diabetes HbA1c control is 49.1% (England 57.4%).
Lipid-lowering therapy exceeds benchmarks at lower unit cost.
Patients with QRISK >= 20% on lipid-lowering therapy reached 72.8% (Pendle 66.2%, ICB 61.4%, England 63.6%) after +19.8% growth, costing £1.40 per item.
Preventive screening, immunisation and asthma review shortfalls.
Cervical screening aged 25-49 is 52.8% (England 66.8%), age-5 MMR2 is 80.9% against the 95.0% target, and an estimated 1,369 asthma patients lack reviews.
Population, age and ethnicity
A young population with 26.3% children and 41.9% Asian residents may shape local need
Across 51,614 registered patients, 26.3% are aged 0-17, exceeding Pendle (22.8%), the ICB (19.6%), and England (19.6%), whereas 14.7% are aged 65+, trailing Pendle (17.0%), the ICB (20.0%), and England (17.9%). In associated Census areas, 41.9% of residents are Asian or Asian British, compared with 26.7% in Pendle, 9.4% in the ICB, and 9.6% in England. This younger age structure may elevate paediatric demand while moderating crude older-age disease prevalence. Note that Census resident ethnicity reflects local catchment areas rather than confirmed practice registrations.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Pendle local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Pendle LA) | 1,461 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 49.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Pendle LA) | 712 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Pendle LA) | 13.6 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 65.4% PCN-wide, spanning 32.0 pp across practices
Across Pendle West PCN, 65.4% of registered patients live in Core20 areas (Pendle 46.6%, ICB 30.6%, England 21.0%), with an average IMD decile of 2.3 (Pendle 3.5, ICB 5.0, England 5.5). The practice-weighted Core20 share is 67.3%, showing a 1.94 percentage point discrepancy against the PCN figure. Practice concentration spans 32.0 pp from Reedyford Hlth Care Group (53.0%) to Whitefield Healthcare (85.0%), while volume concentrates at Nelson Medical Practice (9,118 estimated patients). Targeting both concentration and volume avoids under-serving large deprived cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
582
SMI register
1.09% recorded prevalence
357
Learning disability register
0.67% recorded prevalence
13
Care homes, 424 beds
In the PCN catchment
9.5%
Provide unpaid care
Pendle, Census 2021
The PCN records 357 patients on the learning disability register (0.7% versus 0.5% in Pendle, 0.6% in the ICB, and 0.6% in England) and 582 with severe mental illness (1.1% versus 1.1% in Pendle and 1.0% in England), alongside 424 care-home beds across 13 homes. Catchment bed counts do not confirm registered PCN patients.
Severe mental illness: physical health checks
SMI physical health checks trail England for blood pressure (76.8% versus 83.4%), BMI (73.4% versus 82.1%) and psychosis alcohol recording (67.9% versus 81.8%). Routine monitoring shortfalls indicate an opportunity to systematise annual physical health check recall.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,027
Hypertension register
+2.56%
Register growth, 3 yrs
Pendle +3.69% · England +5.60%
−1.56pp
BP control, under 80
≤140/90 · −0.52pp aged 80+
+466
More patients by 2030
Forecast 7,493 (13.84%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.2% (7,027 patients), below Pendle (14.9%), the ICB (17.2%) and England (15.2%), while three-year register growth of +2.6% trails England (+5.6%). Blood pressure control in patients aged under 80 is 63.5%, behind England (67.8%) and the ICB (67.1%), with a three-year change of -2.4% (England +3.2%). Furthermore, hypertension treated to target is 67.5% (England 70.3%) following a -1.7% three-year change (England +3.6%). Denominators include personalised care adjustments, and observation periods for the register and list size are not confirmed to match. Trailing national blood pressure control benchmarks indicates that prioritising proactive clinical recall and treatment titration for under-80 hypertensive patients is an immediate operational need.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 72.8%, above Pendle (66.2%), the ICB (61.4%) and England (63.6%), following a +19.8% three-year change (England +6.2%). Higher lipid-lowering therapy coverage than England indicates strong primary prevention that the PCN should sustain across cardiovascular pathways.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 96,635 | £1.40 | £1.64 | £1.86 | £135,289 |
| Cardiovascular (all), 2025 | 124,589 | £3.26 | £3.38 | £3.33 | £406,160 |
In 2026, lipid-modifying drugs cost £1.40 per item across 96,635 items, below Pendle (£1.72), the ICB (£1.64) and England (£1.86), spending £44,452 less than at England's unit cost. Spending less per item on lipid-modifying drugs than England leaves financial scope to sustain wide treatment coverage while monitoring appropriate dosing.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.61%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.46%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.6% (England 6.6%), covering 3,756 patients, while 12-month reviews reached 63.5% (England 65.7%), leaving an estimated 1,369 patients unreviewed. Second-hand smoke recording in ages 6-19 is 67.5% (England 78.8%), and asthma management items prescribed per 1,000 aged 5-19 is 1,017 rate (England 1,488 rate). COPD prevalence is 1.8% (England 1.9%) with 77.0% reviewed (England 76.4%).
Cancer register and children's immunisation
Cancer prevalence is 2.7% (England 3.8%), with 1,431 registered patients. Childhood immunisations trail the 95.0% target: at 24 months, MMR1 is 77.1% (England 88.3%) and 6-in-1 is 81.4% (England 92.2%). At age 5, MMR2 is 80.9% (England 82.8%), trailing age-5 MMR1 (93.2%) by 12.3 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage in NHS Lancashire and South Cumbria ICB (4,642 of 8,863) were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 percentage points below the 75.0% national ambition by 2028. Staged data covered 74.6% of registered cancers (8,863 of 11,883). These system figures describe the ICB rather than PCN performance. At PCN level, cervical screening coverage in women aged 25-49 is 52.8% (England 66.8%), including 47.2% at Pwe Pendle Valley Mill, 47.9% at Dr Jehangir (sh), and 49.9% at Whitefield Healthcare; breast screening coverage is 63.3% (England 69.9%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Lancashire Hospitals NHS Trust achieved 81.5% on the cancer 28-day faster diagnosis standard, above the 75.0% standard, Northern Care Alliance NHS Foundation Trust (75.2%), the ICB (78.4%) and England (79.3%), but behind Airedale NHS Foundation Trust (87.7%). On the 62-day referral to treatment standard, the trust reached 73.2%, trailing the 85.0% standard, the ICB (73.6%), Northern Care Alliance NHS Foundation Trust (78.6%) and Airedale NHS Foundation Trust (88.9%). At month end, 0.4% waited 6+ weeks for MRI and 0.1% for CT, below England (21.4% and 9.9%).
| Pathways within standard (%) | East Lancashire | Airedale | Northern Care Alliance | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 87.71 | 75.20 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 98.20 | 94.54 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 88.89 | 78.65 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Airedale | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 0.43 | 2.91 | 5.09 | 21.40 |
| CT | 0.15 | 0.00 | 4.10 | 9.92 |
| Echocardiography | 0.00 | 0.70 | 31.48 | 28.48 |
| Colonoscopy | 0.95 | 31.21 | 40.04 | 30.83 |
| Gastroscopy | 1.16 | 22.98 | 36.48 | 29.02 |
| All 15 DM01 tests | 3.25 | 4.33 | 15.71 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In provisional June 2026 data, 56.9% of community service contacts for Pendle borough residents were for adults aged 65 and over (72,000 of 126,445 contacts). These figures describe borough-wide resident utilisation rather than PCN-level activity. This pattern is consistent with substantial older-age community health needs across the wider area, reinforcing the value of primary care alignment with community services.
Practice variation and patient experience
Easy phone contact spans 43.9 percentage points across captured practices
In 2025/26, QOF overall achievement ranged from 79.9% at Dr Jehangir (sh) to 90.9% at Whitefield Healthcare against England's 92.5%. Vaccination and immunisation achievement lagged England (55.2%) across captured practices, spanning 12.6 pp from 15.6% at Dr Jehangir (sh) to 28.2% at Nelson Medical Practice, while personalised care adjustment rates reached 16.2% at Pwe Pendle Valley Mill.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Whitefield | 105 | 85.0 | 63.7% | 69.3% | 79.9% |
| Pendle View | 101 | 58.5 | 63.4% | 81.3% | 79.3% |
| Reedyford Hlth | 82 | 53.0 | 58.3% | 75.0% | 77.0% |
| Nelson Medical | 101 | 84.0 | 30.0% | 75.3% | 65.1% |
| Dr Jehangir (sh) | 98 | 78.4 | 45.7% | 59.0% | 61.8% |
| Pwe Pendle Valley | 118 | 67.2 | 19.8% | 75.5% | 47.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 measures trail England's three-year trend, led by dementia and reviews
Across 25 compared measures, 14 trail England's three-year change. Dementia QOF prevalence fell 6.7% over three years (Pendle -9.0%, ICB +2.8%, England +6.0%). Annual heart failure functional reviews fell 2.1% (Pendle -4.8%, ICB +1.3%, England +8.7%) to 77.1% (England 78.5%). Psychosis alcohol recording fell 1.7 pp (Pendle +2.4 pp, England +5.4 pp). Conversely, learning disability register rose +13.3% (England +5.4%) and stroke rose +7.2% (England +2.3%). Trailing trends may reflect case ascertainment or list turnover, which practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
Alcohol record (psychosis)
BP control, under 80
Hypertension treated to target
QRISK statin treatment
Breast screening (53-70)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Pendle | Asset | PCN | Pendle |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (424 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 4 | 7 | Places of worship | 42 | 71 |
| Libraries | 4 | 8 | Primary schools (LA maintained) | 15 | 22 |
| Primary academies | 8 | 9 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma review and smoke-recording recall
Of 3,756 asthma patients (7.6% prevalence versus England 6.6%), 63.5% had a 12-month review (England 65.7%), leaving an estimated 1,369 unreviewed; 6-19 second-hand smoke recording is 67.5% (England 78.8%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension titration recall
Across 7,027 hypertension patients (13.2% prevalence), under-80 BP control is 63.5% (England 67.8%, ICB 67.1%) after a -2.4% three-year change (England +3.2%); overall treatment to target is 67.5% (England 70.3%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined SMI physical health checks
Across the 582-patient SMI register, annual checks trail England for BP (76.8% versus 83.4%), BMI (73.4% versus 82.1%) and psychosis alcohol recording (67.9% versus 81.8%, falling 1.7 pp over three years). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted multilingual access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Dual-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment titration (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Paediatric immunisation recall campaign (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Asthma review and smoke-recording recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension titration recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
